NaDeNo

Based in Norway, NaDeNo is a startup. Brouky classifies it under Healthcare & Life Sciences.

NaDeNo develops a nanoparticle-based drug delivery platform to encapsulate and locally deliver hard-to-deliver molecules. Its lead candidate, PACAB-002, is being developed to eradicate peritoneal micrometastases in high-grade serous ovarian cancer and is planned to enter Phase I clinical investigation in early 2027.